Trump’s Drug Price Ultimatum Scambling Pharma Companies

Pharmaceutical companies are disturbing Donald Trump’s president of the US president “binding commitments” requires the “binding commitments” required..

White house said President Trump on Thursday Send letters The 5 17 major pharmacies explaining the steps to lower the US prescription drug price to lower the “largest national difference” (MFN) level until September 29th.

They were told “if they refuse the step,” the government will expand all the tools to protect the abusive prices of drugs in the American families “without expressing what these measures could be.

The companies to receive letters were Abbvie, Nanma, AstrazenecaBoehringer Ingelheim, Bristol-Myers Squibb, Eli LillyEMD Serono, Roche ‘S Genentech subsidiary, Key, GSK, Johnson & Johnson, Merck, Novartis, Novo Nordisk, Pfizer, Resolloonium and Sanofi.

Health shares fell on Friday after the wider market losses, investors were digested by Trump Trade Change Tariffs. Novo Nordisk Wegovy-maker fell by 5% in morning trading, before pairing losses, is 1.3% at 11:15 AM during London times (6:15 AM et).

Companies must provide MFN prices to all Medicaid patients, US health program to low income patients.

They also told not to offer medicines in other developed markets than those offered in the US, and they should sell drugs directly to the US patients, thus cutting the pharmacy Middlemen is known as pharmaceutical benefit manager (PBMS).

Trump has long pharmaceutical pharmacies, before pharmaceutical drugs were pricing for prices, prior to 80%.

In May, the President signed a corrective command Smaller drug costs Linking the prices of some medicines in the US abroad lower bottom of MFN policy.

USA consistently pays the most in the world For many prescription drugs, the US return is a very complex and fragmented and non-national price control.

The last announcement is the pharmaceutical industry Calling clarity In very potential industrial rates. Trump warned them in advance that they could be as high as 200%.

Many companies, however, have shared that they agree with Trump concerns.

Astrazeneca General Manager Pascal Soriot said on Tuesday, Anglo-Swedish closely linked With the US Administration in MFN policy and US investment in a broader way. Last week, he announced the intentions of investing $ 50 billion in the US, following other Pharma companies.

“There are price issues. I personally think the President is right to say that price equalization should take place,” said Sorium in a call for profit.

Vas Narasimhan said the General Manager of Switzerland Last month, the company was looking for MFN policy to lower US drug prices.

A spokesperson from Novo Nordisk said, “Improving the patient’s access and improvement” he would continue to work “to find solutions that help people enter the medicines they need.”

Jpmorgan analysts said in a note on Friday, while the last announcement was wonderful, along with the US Administration, buying some time to respond to Pharma companies.

“Although the last proceeding of the government may be tough, it is likely that it is discussed according to the subject and the government.